Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Tyrosine hydroxylase inhibitors for treatment of aortic aneurysm

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20200402003
Publicado:
26/05/2020
Caducidad:
27/05/2021
Resumen:
Two Spanish research institutions have found the potential of tyrosine hydroxylase inhibitors for prevention and treatment of aortic aneurysm, thus reducing aortic damage. Companies interested in patent licensing and/or in a research collaboration for the development of its application are sought.

Details

Tittle:
Tyrosine hydroxylase inhibitors for treatment of aortic aneurysm
Summary:
Two Spanish research institutions have found the potential of tyrosine hydroxylase inhibitors for prevention and treatment of aortic aneurysm, thus reducing aortic damage.
Companies interested in patent licensing and/or in a research collaboration for the development of its application are sought.
Description:
Aortic aneurysm is a silent but life-threatening vascular disease with no pharmacological strategies for prevention or treatment available, apart from surgical repair. It is associated with hypertension, atherosclerosis, ageing and smoking and characterized by chronic inflammation and aortic vessel wall weakening until rupture, causing patient´s death.
Different types of aneurysm can be found depending of their anatomic location being Abdominal Aortic Aneurysm (AAA) one of the most common forms
Recently it has been discovered the upregulation of tyrosine hydroxylase enzyme in AAA. Presented here is the use of a tyrosine hydroxylase inhibitor to reduce the progression and severity of AAA. This compound has been tested in two mice models (TgNR4A3 transgenic and apoliprotein E-deficient (ApoE-/-), significantly reducing vessel inflammation after aneurysm induction with angiotensin II and limiting structural alteration, near to normal levels after treatment during 28 days.
Tyrosine hydroxylase inhibitors show potential for pharmacological prevention and treatment of abdominal and thoracic aortic aneurysm by reduction of aorta dilatation and vessel weakening.
The research groups, with a broad experience in vascular clinical research, are searching for a biotech or pharmaceutical company interested in the preclinical and clinical development of a treatment for AAA, under a license agreement. The Spanish research centers could collaborate with the company in that project through a research collaboration.
Advantages and Innovations:
·The compound has shown significant efficacy in:
- reducing the incidence and severity of AAA,
- preventing disruption and rupture of elastic vessel laminas,
- limiting the inflammatory infiltrate produced by Ang II.
·Tyrosine hydroxylase inhibitors may represent a promising approach to overcome human aneurysm progression, reducing the risk of aneurysm rupture and death and avoiding surgery and its associated perioperative risk.

Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
PCT patent application filed

Partner sought

Type and Role of Partner Sought:
Biotech or pharmaceutical companies interesed in the development a new treatment for aortic aneurysm.
-Licensing agreement: the partner would license the technology to perform clinical assays, obtain all regulatory
certifications and commercialize the product.
-Research cooperation agreement: the partner and the institution could undertake a joint effort to perform preclinical
assays.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001011 Enfermedades circulatorias y del corazón
06001002 Investigaciones clínicas, ensayos
06001015 Productos farmacéuticos / medicamentos